• Biodefense Therapeutics, of Fort Belvoir, Va. (a joint product management office within the U.S. Department of Defense through a contract with Boston-based Medivector Inc.) reported the successful completion of a Phase II double blind placebo-controlled trial for the anti-influenza drug, T-705a (favipiravir), which clears the way for Phase III trials to begin in November.